Three Monsters Under Growth Investors' Beds

 

Stock Market Video

Three Monsters Under Growth Investors' Beds

This Week's Fortune Cookie

In Case You Missed It

---

In this week's Stock Market Video, Mike Cintolo, Chief Analyst of Cabot Growth Investor and Cabot Top Ten Trader, is growing a bit more optimistic, and it's not just because the market has rallied for the past few days. He's seeing some strong stocks hold and even extend their gains while other growth stocks have pulled back and held support. He advises being selective and suggests a few stocks you might want to consider. Click below to watch the video.

---

Three Monsters Under Growth Investors' Beds

If you were looking at a roomful of stock investors and wanted to figure out which ones were growth investors and which preferred the value discipline, it might be pretty easy, especially if the stock markets were open at the time.

All you'd have to do is look for which ones were nervously checking their smartphones to see how their stocks were doing. And then re-checking them 15 minutes later. Then again. And again.

The value investors, in the meantime, would be reading magazines, napping or quietly flipping through annual reports in search of a scrap of useful information about projected market share or free cash flow.

So why are growth investors jumpier than value investors?

Well, in general, growth stocks are just more volatile than value stocks, almost by definition. Charts of growth stocks show more movement and their up and downswings cover more ground. Plus, growth investors have more-concentrated portfolios than value investors. The growth investor wants any big win to have a significant effect on his total portfolio, while the value investor aims to spread the risk around so that any big loss will have a negligible effect on performance.

As a growth investor, I've spent years studying the things that drive growth investors crazy, and I have a little list I'd like to share with you. I even have some recommendations for how to keep your blood pressure down while playing the growth game.

Earnings Misses

Four times a year, following requirements set down by the Securities and Exchange Commission, all companies whose stocks trade on U.S. exchanges must tell people how they did during the previous three months. The report must include revenues, earnings and events such as acquisitions that might have affected the results.

Analysts covering the companies predict what those numbers will be, and that sets up a very dramatic event. If analysts' "consensus" estimate is that the company will earn 30 cents per share on sales of $100,000,000 and the earnings come in at 31 cents and revenue at $101,000,000, it's a triumph! That's labeled a "beat" and the stock (generally) goes up.

If, on the other hand, earnings are only 29 cents per share and/or revenues are only $99,000,000, it's a "miss," and the stock (usually) drops significantly.

How can you stay calm during earnings season?

First, you should know exactly what your loss limits are on each of your stocks. If a stock falls out of bed and hits your maximum loss limit, you sell it. When there is no doubt about what to do, there is no hesitation in doing it.

Second, you should know exactly when a company is reporting and avoid buying a full position in a stock just ahead of earnings; quarterly reports are too much of a coin flip to make big bets on. And third, you might consider taking a little profit in a big winner ahead of the report.

Bad News

Even outside earnings season, bad news can take a toll on growth stocks. Losing a big contract, being confronted by a new competitor, natural disasters, labor problems ... all these can undercut investors' confidence in a stock. Many industries have built-in opportunities, especially pharmaceutical stocks, which face intense scrutiny when clinical trial results on candidate drugs are announced.

Then there's the Bad News that rises to the level of scandal, which can be near-fatal for stocks. (See Lumber Liquidators (LL) recently). Any hint that a company is under investigation for fudging its results or otherwise fiddled with its accounting can send investors toward the exit in a stampede.

As with earnings season, the best response to bad news lies in how you prepare for it. If your sell disciplines are in good shape, especially your loss limits, you won't have to worry about controlling losses. When a stock drops below your limit, hit the sell button.

Missing the Big Winner

Often the biggest pain a growth investor feels isn't caused by a loss; growth investors get used to taking an occasional left hook to the ribs. Some of the most plaintive questions we get from subscribers involve stocks that have run away to the upside. "Is it still buyable?" "Will it pull back to let us in?" The pain of missed opportunity is real for growth investors, who get huge pleasure from (and whose results are often based in large part on) riding a big winner.

Unfortunately, there's no perfect cure for this problem. Big winners can make astonishing runs while you're having your second cup of coffee. But remember that a majority of a growth investor's gains comes from the action of just a few winners every year. So even if you miss a winner, there will be others, especially if the general trend of the market is up.

Sometimes you can get in on a big gainer after a pullback or consolidation. After all, one of the Cabot rules of growth investing is that trends can go on for much longer than you think. If you need confirmation of this, just take a look at the chart for Apple (AAPL) starting in the beginning of 2009 through late 2012. Besides soaring from 11 to 100, the stock also presented plenty of dips along the way that represented buying opportunities.

The other tip for not missing big winners is, predictably, a subscription to Cabot Top Ten Trader. This publication is legendary for finding big leaders early in their advances and letting subscribers know why they are strong, what the chart tells us and where to buy them. It's an exciting weekly read for growth investors and you can give it a try with a trial subscription by clicking right here.

---

Here's this week's Fortune Cookie. Remember, you can always view all previous Fortune Cookies here and Contrary Opinion buttons here. 

Tim Lutts' comment: Knowing (and having experienced) Mr. Peter's famous principle firsthand, I have no doubt that a large part of the world's ills are the result of well-meaning people tasked beyond their capabilities. The remedy is education.

Mike Cintolo's comment: I generally agree with Tim; rarely do I think people are acting out of spite, rather, they're just making honest mistakes. But applying this to the market, my main thought is: Don't worry about it. Sure, there are some people out there with nefarious goals, but whatever it is, it is. Your job is to form a winning plan and stick to it-no amount of imbecilic decisions or con jobs will harm you as long as you're consistently putting the odds in your favor.

---

In case you didn't get a chance to read all the issues of Cabot Wealth Advisory this week and want to catch up on any investing and stock tips you might have missed, there are links below to each issue.

Cabot Wealth Advisory 5/18/15 - One Simple Rule that Can Save Your Portfolio 

In this issue, I jump on the "one simple rule" bandwagon that seems to be sweeping the Internet to give you an investing idea that can save your portfolio when things get stormy. Stock discussed: JetBlue (JBLU).

Cabot Wealth Advisory 5/19/15 - A Stock with an Attractive Price/Sales Ratio 

Our value expert Roy Ward describes one calculation he uses to find undervalued stocks that will consistently outperform the stock market indexes. Stock discussed: SYNNEX (SNX).

Cabot Wealth Advisory 5/21/13 - Top 5 Reasons Most Investors Don't Make Big Money 

Mike Cintolo, our chief growth guru, takes a look at the five biggest mistakes growth investors make ... and some ideas on how to correct them. Stock discussed: SolarCity (SCTY).

Have a good weekend,

Paul Goodwin
Chief Analyst of Cabot China & Emerging Markets Report
And Editor of Cabot Wealth Advisory


Paul Goodwin can be found on Google Plus.

Stock Picks

Loews Corp.

This undervalued stock has strong future earnings growth expectations.

Biogen

Biogen is the market-share leader in treating multiple sclerosis.

Weibo

One of Paul Godwin’s favorite stocks in his Cabot Emerging Markets Investor portfolio.

Cabot Wealth Advisory

Does Alibaba (BABA) Stock Measure Up to Amazon (AMZN)?

By Paul Goodwin on September 23, 2016

Alibaba (BABA) is the Amazon (AMZN) of China. But does BABA stock measure up to AMZN stock? Let’s break it down!Read More >

As Stock Market Trends Change, Invest in these New Leaders

By Michael Cintolo on September 22, 2016

History tells us that all stock market trends change, and if you don’t recognize the leaders of that change early, you risk missing out on the next big winners.Read More >

AMZN Stock vs. FB Stock: Which Is the Better Value Buy?

By J. Royden Ward on September 20, 2016

For the past five years, AMZN stock and FB stock have been two of the market's great growth stories. But could you make the case that either stock is still undervalued? Let’s break it down.Read More >